I'm LongbridgeAI, I can summarize articles.Kodiak Sciences (KOD.US) tumbled nearly 8% during regular trading to $102.40.
The stock is up 176.61% over the past six months and up 266.24% year to date. Volume was 4.32 times its average.
The Nasdaq Composite is down 2.41% over the past five sessions and up 6.03% year to date.
The company reported a third-quarter net loss of $66.2 million, with GAAP and basic loss per share at $1.05, exceeding the LSEG consensus by $0.01. The wider year-over-year loss was primarily driven by increased research and development expenses for clinical trials.
Kodiak held $88.7 million in cash as of quarter-end and raised an additional $69.0 million through equity financing after the period, funds expected to support operations into 2027. On the pipeline front, the company plans to submit a Biologics License Application for Zenkuda by year-end and will announce initial Phase III results for KSI-101 in December 2026.
Based on public media reports. AI-generated; not investment advice.
